Sort
48,018 grants matching “immunotherapy”
Epigenetic mechanisms of transcriptional activation of a novel oncogenic ALK variant in cancer
$483,730Ping Chi · Sloan-Kettering Inst Can Research · R01 · FY2019 · CA
Imaging Costimulation Blockade Resistant Rejection
$483,714Andrew B Adams · Emory University · U01 · FY2017 · AI
Project 2: Combined CAR-T cell therapy
$483,710Gianpietro Dotti · Univ Of North Carolina Chapel Hill · P50 · FY2023 · CA
Non-coding RNA regulation of Myeloid Cells
$483,706Jorge Henao-Mejia · University Of Pennsylvania · R01 · FY2024 · CA
Optimized ultrasound-enhanced immunotherapy
$483,694Katherine W Ferrara · Stanford University · R01 · FY2019 · CA
Exploiting a novel regulator of immunometabolism to enhance immunotherapy
$483,665Edward John Usherwood · Dartmouth College · R01 · FY2023 · CA
Improving the translational value of head and neck cancer patient-in-mouse models
$483,592Randall J Kimple · University Of Wisconsin-Madison · R37 · FY2024 · CA
Novel biologic RNA molecules to modulate HCC metabolism
$483,591Aiming Yu · University Of California At Davis · R01 · FY2025 · CA
Novel biologic RNA molecules to modulate HCC metabolism
$483,591Aiming Yu · University Of California At Davis · R01 · FY2024 · CA
Basophil phenotype & activation in peanut allergy and oral Immunotherapy
$483,584Stephen J Galli · Stanford University · U19 · FY2014 · AI
Targeting autophagy to enhance immune checkpoint inhibition
$483,579Ravi K Amaravadi · Wistar Institute · P50 · FY2025 · CA
Targeting Small Nucleolar RNA Augments Immunotherapeutic Efficacy
$483,568Chunru Lin · University Of Tx Md Anderson Can Ctr · R01 · FY2022 · CA
Novel roles of STAT2 and IFN-I in tumorigenesis and responses to therapy
$483,558George Robert Stark · Cleveland Clinic Lerner Com-Cwru · P01 · FY2025 · CA
Novel roles of STAT2 and IFN-I in tumorigenesis and responses to therapy
$483,558George Robert Stark · Cleveland Clinic Lerner Com-Cwru · P01 · FY2022 · CA
Neoadjuvant checkpoint blockade for recurrent glioblastoma
$483,557Robert M Prins · University Of California Los Angeles · R01 · FY2023 · CA
TLR Agonist Nano-Immune Therapy for Peritoneal Metastases
$483,556Rita Elena Serda · University Of New Mexico Health Scis Ctr · R01 · FY2024 · CA
Biomaterials for modulating the gut microbiome for immune activation
$483,524James J. Moon · University Of Michigan At Ann Arbor · R01 · FY2023 · CA
Membrane-based immunotherapy for triple negative breast cancer- a partnered approach
$483,484Periasamy Selvaraj · Emory University · R01 · FY2018 · CA
Project 1: Overcoming therapeutic resistance in pancreatic cancer through epigenetic reprogramming
$483,451Ronald M. Evans · Salk Institute For Biological Studies · P01 · FY2024 · CA
In situ Redirection of T cell Specificity and Imaging of Targeted CAR Expression.
$483,404Zelig Eshhar · Tel-Aviv Sourasky Medical Center · R01 · FY2016 · EB
Estrogen Suppression as a Strategy to Enhance Immunotherapy Efficacy in EGFR-Mutated Non-Small Cell Lung Cancer
$483,395Joseph Nicholas Bodor · Research Inst Of Fox Chase Can Ctr · R21 · FY2024 · CA
A novel engineered IL-21-based immunocytokine as a therapeutic approach for tumor targeting in renal cancer
$483,395Petr B. Makhov · Research Inst Of Fox Chase Can Ctr · R21 · FY2024 · CA
4DN Interrogation of T Cell Exhaustion in Cancer
$483,367Ansuman Satpathy · Stanford University · U01 · FY2024 · CA
Targeting Systems Vulnerabilities in the EGFR/HER3/HER2 Oncogenic Signaling Circuitry: New Precision Therapies for Oral Cancer
$483,360J. Silvio Gutkind · University Of California, San Diego · R01 · FY2025 · DE
Targeting PPT1 in the Tumor Microenvironment
$483,340Ravi K Amaravadi · Wistar Institute · P01 · FY2021 · CA